Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx director William C. Bertrand Jr. reported equity-based compensation grants. On June 16, 2026, he received 26,455 shares of common stock issued under Ardelyx’s Non-Employee Director Compensation Program after electing to take stock instead of cash fees.
He was also granted restricted stock units that convert into one share of common stock per unit upon vesting, issued under the same director program. In addition, he received a stock option for 39,715 shares at an exercise price of $5.67 per share, expiring June 16, 2036, which vests monthly with potential accelerated vesting at the next annual stockholders’ meeting.
ARDELYX, INC. director Robert B. Bazemore received equity compensation consisting of both shares and options. He was granted 26,455 restricted stock units, each convertible into one share of common stock upon vesting under the Non-Employee Director Compensation Program, bringing his direct holdings to 68,006 shares. He also received a stock option for 39,715 shares at an exercise price of $5.67 per share, vesting in 12 monthly installments and expiring on June 16, 2036, with unvested portions accelerating at the next annual stockholders’ meeting if he continues in service.
Ardelyx, Inc. reported results of its 2026 Annual Meeting, where stockholders approved all five proposals, including changes to its long-term incentive plan and auditor ratification.
Stockholders elected three Class III directors to serve until the 2029 Annual Meeting. They approved, on a non-binding basis, the company’s Say-On-Pay proposal and selected an annual Say-On-Pay vote, with 141,539,889 votes cast for a one-year frequency.
Investors ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 186,182,340 votes in favor. They also approved the Second Amendment to the Amended and Restated 2014 Equity Incentive Award Plan.
ARDELYX, INC. President & CEO Michael Raab reported mixed equity activity in company stock. He sold 41,666 shares of common stock on June 15, 2026 at a weighted average price of $5.6724 per share in an open-market transaction made under a Rule 10b5-1 trading plan adopted on November 7, 2025. On the same date, he exercised stock options to acquire 20,833 common shares at an exercise price of $0.99 per share. Following these transactions, he holds 1,699,200 shares of common stock directly, along with additional indirect holdings of 1,000 and 24,364 shares through family trusts, and 311,668 stock options remaining outstanding.
Ardelyx insider reported proposed and executed sales of Common Stock. Michael G. Raab reported multiple dispositions: 54,748 shares on 05/21/2026 for $343,133.09, 41,666 shares on 05/15/2026 for $261,610.40, 41,668 shares on 04/15/2026 for $261,954.22, and 41,666 shares on 03/16/2026 for $243,329.44. The filing lists prior grant sources including stock option exercises, restricted stock units, and an employee stock purchase plan.
ARDX reporting person submitted a Form 144 to sell 125,000 shares of Common Stock. The notice lists proposed sales tied to option exercises, restricted stock unit vesting, and an employee stock purchase plan. Recent executed 10b5-1 sales by Michael G. Raab totaled 179,748 shares across 03/16/2026–05/21/2026, with proceeds shown per trade.
ARDELYX, INC. officer Joseph James Reilly reported selling a total of 3,719 shares of common stock at an average price of $6.2675 per share. According to the footnotes, these sales were automatic sell-to-cover transactions triggered by the vesting of restricted stock units and were made solely to cover withholding taxes. After the sales, he directly holds 149,107 shares of Ardelyx common stock. The holdings include 1,765 shares acquired under the company’s employee stock purchase plan on February 27, 2026.
Ardelyx, Inc. Chief Financial Officer Susan Hohenleitner reported a small tax-related share sale. She disposed of 1,455 shares of common stock on May 21, 2026 at an average price of $6.2675 per share. A footnote explains the transaction was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes rather than as a discretionary open-market sale. After this transaction, she directly holds 229,078 Ardelyx common shares.
ARDELYX, INC. officer John E. Bishop reported a small sale of common stock tied to restricted stock unit (RSU) vesting. He disposed of 2,306 shares at an average price of $6.2675 per share, and held 336,845 shares afterward.
According to the footnote, the transaction was an automatic sell-to-cover required by the original RSU grant terms, with shares sold solely to pay applicable withholding taxes. This indicates a routine, compensation-related tax event rather than a discretionary open-market sale based on a view of the stock.
ARDELYX, INC. reported that Chief Human Resources Officer Brady James Parker had 1,846 shares of common stock sold at an average price of $6.2675 per share. According to the footnote, this automatic sell-to-cover transaction occurred upon RSU vesting to satisfy withholding taxes, leaving him with 261,066 shares directly owned.